Dr. Bin Hu 胡滨
Chief Physician
Department of Urology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of urinary system tumors using laparoscopy, da Vinci robot, and open surgery. Expertise includes kidney, prostate, bladder, ureteral, adrenal, and testicular cancers, as well as radiofrequency ablation and multidisciplinary care for advanced cases.
Dr. Hu is Chief of Urology at Liaoning Cancer Hospital & Institute and a master’s supervisor at China Medical University and Dalian Medical University. Dr. Hu performs high-volume da Vinci robotic surgeries and offers radiofrequency ablation for patients unable to tolerate surgery. Dr. Hu leads a multidisciplinary team recognized as an Excellent MDT Center by CACA-GU and participates in national and global clinical drug trials.
Professional roles
- Chair, Urologic Oncology Professional Committee, Liaoning Anti-Cancer Association (Designate)
- Chair, Urologic Oncology Professional Committee, Liaoning Life Society
- Vice Chair, Andrology Society, Liaoning Medical Association
- Standing Committee Member, Urology Branch, Liaoning Medical Association
Name order: in Chinese the family name comes first (Hu Bin). Papers usually list the name as Bin Hu or Hu B.
Selected publications
24 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Surg, 2024 (senior author): Meta-analysis of clinical outcomes of robot-assisted partial nephrectomy and classical open partial nephrectomy. PubMed 38573087
- Transl Res, 2024 (senior author): Knockdown of ADAM8 inhibits the proliferation, migration, invasion, and tumorigenesis of renal clear cell carcinoma cells to enhance the immunotherapy efficacy. PubMed 37992987
- Front Microbiol, 2023 (senior author): Effects of gut microbiota on prostatic cancer: a two-sample Mendelian randomization study. PubMed 38029073
- Front Oncol, 2023 (senior author): Meta analysis of clinical prognosis of radiofrequency ablation versus partial nephrectomy in the treatment of early renal cell carcinoma. PubMed 37182152
- Jpn J Clin Oncol, 2022 (senior author): Identification of distinct genomic features reveals frequent somatic AHNAK and PTEN mutations predominantly in primary malignant melanoma presenting in the ureter. PubMed 35578896
- J Oncol, 2022 (senior author): A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma. PubMed 35386213
- Cell Biol Int, 2021 (senior author): Exosomes-mediated transfer of long noncoding RNA LINC01133 represses bladder cancer progression via regulating the Wnt signaling pathway. PubMed 33728699
- Front Oncol, 2020 (senior author): Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma. PubMed 33102202
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion